3-[(4-chlorophenyl)sulfonyl]-5-fluoro-2-methylindole-1-acetic acid | 646515-59-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3-[(4-chlorophenyl)sulfonyl]-5-fluoro-2-methylindole-1-acetic acid
• 英文别名: 2-[3-(4-Chlorophenyl)sulfonyl-5-fluoro-2-methylindol-1-yl]acetic acid
• CAS: 646515-59-5
• 化学式: C₁₇H₁₃ClFNO₄S
• 分子量: 381.812
• InChiKey: AQXNOXJAJOOFPU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  84.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  3-[(4-chlorophenyl)thio]-5-fluoro-2-methylindole-1-acetic acid 在 间氯过氧苯甲酸 作用下， 以 乙腈 为溶剂， 反应 3.0h， 生成 3-[(4-chlorophenyl)sulfonyl]-5-fluoro-2-methylindole-1-acetic acid
  参考文献：
  名称：

  [EN] INDOLE-3-SULPHUR DERIVATIVES
  [FR] DERIVES D'INDOLE-3-SOUFRE

  摘要：

  本发明涉及作为治疗呼吸系统疾病的药用化合物有用的取代吲哚。 (I)

  公开号：

  WO2004007451A1

文献信息

• Indole-3-sulphur derivaties
  申请人：Bonnert Roger

  公开号：US20060111426A1

  公开（公告）日：2006-05-25

  The present invention relates to substituted indoles useful as pharmaceutical compounds for treating respiratory disorders. (I)

  本发明涉及用作治疗呼吸系统疾病的药物化合物的取代吲哚。 (I)
• Indole-3-Sulphur Derivatives
  申请人：Bonnert Roger

  公开号：US20100197756A1

  公开（公告）日：2010-08-05

  The present invention relates to substituted indoles useful as pharmaceutical compounds for treating respiratory disorders. (I)

  本发明涉及取代吲哚，其作为治疗呼吸系统疾病的药物化合物有用。(I)
• INDOLE-3-SULPHUR DERIVATIVES
  申请人：AstraZeneca AB

  公开号：EP1551802B1

  公开（公告）日：2009-12-02
• USE OF CRTH2 ANTAGONIST COMPOUNDS
  申请人：Oxagen Limited

  公开号：EP2219645A2

  公开（公告）日：2010-08-25
• Use of CRTH2 Antagonist Compounds
  申请人：Hunter Michael George

  公开号：US20110124683A1

  公开（公告）日：2011-05-26

  The invention relates to compounds of general formula (I): wherein R 1 , R 2 , R 3 , R 4 and R 5 are as defined herein for the treatment of allergic conditions, wherein the treatment is by pulsed therapy which comprises a first period during which the compound is administered to the patient and a second period of at least seven days during which the compound is administered to the patient in a reduced amount. The invention also relates to compounds of general formula (I) for desensitizing the immune system of a subject to allergens, thus preventing or reducing the symptoms of allergic conditions such as allergic asthma, allergic rhinitis, or atopic dermatitis.